An association between appetite-suppressant medications and cardiac
valve disorders is now generally believed to have been established, but remains
an important scientific and clinical issue. Even though the 2 most commonly
implicated agents, fenfluramine and dexfenfluramine, were withdrawn from the
US market in 1997 and despite the recent multibillion dollar class action
settlement by the manufacturer of these drugs,1
ongoing research continues to attempt to more accurately and more completely
characterize the pathophysiology and natural history of anorexigen-associated
valvular heart disorders. However, the totality of the evidence to date favoring
a causal connection between fenfluramines and cardiac valve disorders is persuasive,
if somewhat complex.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 12
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.